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Summary
Late Gadolinium Enhancement (LGE) has been shown
to be a poor prognostic indicator in LV failure. How-
ever, it has not been studied in predicting adverse prog-
nosis in Pulmonary Hypertension (PH). Herein we show
that LGE enhancement predicts major adverse clinical
events (MACE) in PH patients.
Background
Introduction: Right ventricular (RV) function predicts
prognosis in pulmonary hypertension (PH) patients (pts)
and Right Ventricular (RV) failure. Prior studies evaluat-
ing of 3D RV ejection fraction (EF) have yielded incon-
sistent prognostic information. Here we explore the
prognostic value of contrast enhanced CMR in PH
(WHO group 1-5) patients.
Hypothesis
We hypothesize that myocardial Late Gadolinium
Enhancement (LGE), a marker for myocardial fibrosis
when present in RV or RV insertion points (RVIP), is a
predictor of adverse prognosis in PH pts.
Methods
A retrospective chart review of PH pts (n=42) who
underwent clinically indicated CMR were analyzed.
Demographic data showed mean age 61 yrs; 26% male;
55% WHO group 1 21% group 2, 5% group 3, 14%
group 4, 5% group 5. RV volumetric data were indexed
to BSA, and along with RVIP LGE information, were
correlated with major adverse clinical events (MACE)
including hospitalization, death, referral/need for lung
transplantation and need for addition/increase in
inotropic therapy. In WHO group 2, lung transplanta-
tion was not a MACE event as it is not a relevant clini-
cal option.
Results
LGE was positive (+) in 18 pts (43%) and negative (-) in
the remaining 24 pts (57%). The predominant MACE
events occurs in the LGE+ group (78%). Specifically, in
LGE+ group, 7 pts (39%) had MACE while 11 pts (61%)
did not have MACE. In comparison, the LGE- group
had only 2 pts (8%) who had MACE and 22 pts (92%)
who did not have MACE, <0.03 for all). The results
were similar when WHO group 1 were subanalyzed. In
WHO 1 subgroup 11 pts (48%) were LGE+ and 12 pts
(52%) were LGE-. In the LGE+ group 4pts (36%) had
MACE while 7 pts (64% did not. In the LGE- there
were no MACE, (<0.04). Fisher’se x a c tt e s tw a su s e df o r
group comparisons. Univariate analysis revealed only
RVESVI, RVEF, RVEDVI and MRI LGE predicts MACE.
However, via multivariable logistic regression analysis
only RVESVI (OR: 1.1, 95%; CI 1.0-1.2) and MRI LGE
(OR: 7.0,95%;CI 1.2-39.5) predict MACE. (c2=22.5,df=2,
N=42, p<0.001).
Conclusions
Late Gadolinium Enhancement is a seven-fold stronger
predictor of MACE than standard CMR metrics. LGE’s
role as an independent adverse prognosticator may
define the pathophysiologic hallmark in PH patients as a
direct reflection of underlying RV failure due to progres-
sive myocardial fibrosis.
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